Global Pharmaceutical R&D
MediCane’s global multi-site pharmaceutical and medical R&D consists of preclinical and clinical trials in various therapeutic areas.
Our R&D activities are carried out in-house by our experienced team and through collaboration with world-renowned scientists and leading research institutions, which provide the analytical, biological, and medical expertise. MediCane works to create and protect the intellectual property of its own products and in licensed products in collaboration with leading patent offices.
The Endocannabinoid System
The endocannabinoid system (ECS) is a widespread molecular system that plays important roles in regulating and balancing many physiological pathways in the human body.
The ECS is comprised of the cannabinoid receptors (CB1 and CB2), other non- CB1, non-CB2 receptors (e.g. GPR55, GPR18, TRPV1), the endogenous cannabinoids (endocannabinoids),
and the enzymes involved in the synthesis and degradation of the endocannabinoids
(e.g DAGL, MAGL, FAAH).
All these vital processes make the ECS a key target for potential therapies.
Aizpurua-Olaizola O et al.; Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today. 2017; 22(1):105-110.
As part of its research activities, MediCane takes a wholesome approach and controls every phase of its manufacturing processes, selecting the most effective and safe solutions to achieve medical effect.
Using a patient-centric approach to clinical trials, MediCane aims to provide potent cannabis-based pharmaceutical products to treat inflammatory and neurological diseases.
MediCanes research is conducted in our state-of-the-art R&D facility that includes Analytical and Biological capabilities.